Evidence map›Paper›PMID 38213534›Full record

ReviewExploration of targeted anti-tumor therapy2023

Telehealth in breast cancer following the coronavirus disease 2019 pandemic.

Jean Zeghondy, Elie Rassy, Pietro Lapidari, Roland Eid, Barbara Pistilli

Open access · diamondAbstract readReview
In one paragraph

Review in Exploration of targeted anti-tumor therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Jean ZeghondyMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.ORCID https://orcid.org/0000-0001-8811-4085
Elie RassyMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.ORCID https://orcid.org/0000-0002-7906-0991
Pietro LapidariMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.
Roland EidMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.
Barbara PistilliMedical Oncology Department, Gustave Roussy, F-94805 Villejuif, France.ORCID https://orcid.org/0000-0002-9184-7199
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak, a respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, a pandemic. During this time, cancer patients were heavily impacted and their treatment plans were changed due to measures to fight the disease and solutions had to be found to maintain their follow-up and management from a distance. Some cancer groups worldwide have recommended then the use of telemedicine for oncology patients to ensure the continuity of medical care during the pandemic. This method was considered effective and clinicians worldwide continued using telehealth even after the cessation of worldwide restrictions. To this end, current up-to-date data on the use of telemedicine in BC patient after the COVID-19 outbreak are summarized in this narrative review.

Indexed as

breast cancerbreast neoplasmscoronavirus disease 2019pandemicTelehealthtelemedicine

Identifiers

PMID38213534
PMCPMC10776597
OpenAlexW4390245273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.